21 February 2008, Melbourne: The Directors of HealthLinx Limited (ASX:HTX) are pleased to announce the appointment of Professor Gregory Rice as Non Executive Chairman of the Company.
Professor Rice is a co-founder of HealthLinx and a co-inventor of key patents that underpin HealthLinx’s product development goals. He was appointed as a director of the Company following the reverse acquisition of Cryptome Pharmaceuticals Limited on 14 February 2006 and has been a director since that time.
For the last 6 months, in addition to his role as a director, Professor Rice has also provided science and operations services to the Company under a separate contract and has agreed to continue providing those services for the foreseeable future.
Nick Gatsios, HealthLinx Limited 03 9208 4200
Rudi Michelson (Monsoon Communications) 03 9620 3333
About HealthLinx Limited (ASX:HTX)
HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial targets are: Ovarian cancer diagnostic (OvPlex) targeting US$260m pa market
Pregnancy diagnostic. This would be used in a woman’s first prenatal visit to identify whether she is at high risk of pregnancy complications. Currently there is no product on the market for early stages of pregnancy.
A biomarker is a specific biochemical in the body that is used to measure progress of disease or the effects of treatment.
HealthLinx targets important markets with unmet needs. HealthLinx is developing product applications to successful Phase II biomarker trials and will then seek to out-license to partners for upfront and milestone payments and royalties on sales.
The company also has significant IP in Protein Depletion Technologies (ClearIT™) that depletes serum and other biological fluids of high abundant proteins. HealthLinx offers a fee for service to access the Cryptomics Platform that screens and identifies bio-active peptides for nutraceutical, functional foods and biological applications.